Slide 1 of 1 
Equine IFN beta 1 Recombinant Protein
- Catalog Number:
- RP0935E
- Availability:
- In stock
- Application:
- Cell Culture, ELISA Standard, ELISpot Control, Western Blot Control
- 100% Homology:
- Equus caballus (horse)
- Equine IFN-β1 (catalog RP0935E) is a yeast-derived cytokine supplied lyophilized without carrier protein in 10% trehalose; it has no affinity tags and is naturally endotoxin-free, and should be reconstituted in sterile PBS that contains at least 0.1% carrier protein. The protein is ~19.5 kDa, 165 amino acids long (full sequence provided), and >98% pure by SDS-PAGE, with 100% amino-acid homology to horse. Store at -20°C (stable up to twelve months from date of receipt; working aliquots with carrier protein stable ~3 months) and avoid repeated freeze/thaw cycles. Product origin is the USA. It is commonly used to study type I interferon signaling and antiviral immune responses (including regulation of innate immunity and gene expression); typical experimental uses include cell-culture stimulation and antiviral assays, signaling and gene-expression studies, ELISA and neutralization assays, flow-cytometry and Western blot controls, and antibody generation/validation. Kingfisher Biotech products are supplied for research applications and are not intended for medicinal, diagnostic, or therapeutic use.
| Amino Acid Sequence | VNYDLLRSQL RSSNSACLML LRQLNGAPQR CPEDTMNFQV PEEIEQAQQF QKEDAALVIY EMLQHTWRIF RRNFASTGWN ETIVKNLLVE VHLQMDRLET NLEEIMEEES STWGNTTILR LKKYYGRISQ YLKAKKYSHC AWTVVQAEML RNLAFLNGLT DYLQN (165) |
| Endotoxin | Naturally endotoxin-free |
| Storage Conditions | -20°C |
| Molecular Weight | 19.5 kDa |
| Purity | >98% as visualized by SDS-PAGE analysis. |
| Country Of Origin | USA |
- Equine Interferon-Beta (IFN-β) is a type I interferon produced primarily by virus-infected epithelial cells, fibroblasts, macrophages, and dendritic cells in horses (Equus caballus), where it serves as a key early mediator of innate antiviral immunity. Following recognition of viral nucleic acids by pattern recognition receptors such as RIG-I-like receptors and the cGAS-STING pathway, equine IFN-β is rapidly induced and signals through the type I interferon receptor complex (IFNAR1/IFNAR2), activating JAK/STAT signaling and promoting expression of interferon-stimulated genes (ISGs) that suppress viral replication, enhance antigen presentation, and stimulate natural killer (NK) cell and adaptive immune responses. IFN-β is critically involved in host defense against important equine viral pathogens including equine influenza virus, equine herpesvirus-1 and -4 (EHV-1/EHV-4), West Nile virus, and equine arteritis virus, and the timing and magnitude of IFN-β production can influence viral control, inflammation, and clinical outcome. Viral evasion or dysregulation of IFN-β signaling may contribute to persistent infection or immunopathology. In veterinary and translational research, characterization of equine IFN-β supports studies of respiratory and neurotropic viral pathogenesis, antiviral therapeutics, vaccine development, and comparative type I interferon biology in large-animal models relevant to both equine and human infectious disease research.
Please choose a size to see price
RELATED MEDIA
